Implementation of a "hypoglycemia kit" in a pediatric emergency room: A retrospective study during 2011-2019

Faustine Dulion1, Franklin Ducatez2, Abdellah Tebani3

  • 1Department of Pediatric Emergency, Rouen University Hospital, 76000, Rouen, France.

Insights

The hypoglycemia kit is not cost-effective in pediatric emergencies, with only 2.4% diagnostic efficiency. A new decision tree can improve its targeted use for hypoglycemia investigations.

Area of Science:

  • Pediatric Endocrinology
  • Clinical Chemistry
  • Health Economics

Background:

  • Hypoglycemia is a common pediatric symptom with potential neurological consequences.
  • While often benign, hypoglycemia can indicate serious underlying conditions.
  • A hypoglycemia kit was implemented in 2011 to expedite etiological investigations in pediatric emergencies.

Purpose of the Study:

  • To evaluate the cost-effectiveness of the hypoglycemia kit.
  • To refine the indications for using the kit to improve efficiency.

Main Methods:

  • Retrospective, non-interventional, single-center study.
  • Analysis of digital records from September 2011 to August 2019.
  • Inclusion of 82 pediatric patients who underwent hypoglycemia kit analysis.

Main Results:

  • Functional hypoglycemia was diagnosed in 74 patients (90.2%).
  • The kit directly led to a diagnosis in only 2 cases (2.4% efficiency).
  • History of congenital malformations or prior hypoglycemia correlated with severe etiologies.

Conclusions:

  • The hypoglycemia kit demonstrated low cost-effectiveness in pediatric emergencies (2.4%).
  • Functional hypoglycemia is the predominant cause in this setting.
  • A refined decision tree is proposed to enhance the kit's diagnostic utility and efficiency.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
273
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
182